Profound Medical Corp (PRN) - Total Liabilities
Based on the latest financial reports, Profound Medical Corp (PRN) has total liabilities worth CA$102.04 Million CAD (≈ $73.81 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PRN operating cash flow to assess how effectively this company generates cash.
Profound Medical Corp - Total Liabilities Trend (2014–2025)
This chart illustrates how Profound Medical Corp's total liabilities have evolved over time, based on quarterly financial data. Check PRN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Profound Medical Corp Competitors by Total Liabilities
The table below lists competitors of Profound Medical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunrex Technology Corp
TW:2387
|
Taiwan | NT$8.46 Billion |
|
Thoresen Thai Agencies Public Company Limited
BK:TTA-R
|
Thailand | ฿17.54 Billion |
|
IAR Systems Group AB (publ)
ST:IAR-B
|
Sweden | Skr248.00 Million |
|
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
|
USA | $11.25 Million |
|
Kogan.com Ltd
AU:KGN
|
Australia | AU$129.62 Million |
|
Humedix Co Ltd
KQ:200670
|
Korea | ₩23.40 Billion |
|
Metro Mining Limited
F:6ME
|
Germany | €202.60 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Profound Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Profound Medical Corp market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Profound Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Profound Medical Corp (2014–2025)
The table below shows the annual total liabilities of Profound Medical Corp from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$102.04 Million ≈ $73.81 Million |
+939.91% |
| 2024-12-31 | CA$9.81 Million ≈ $7.10 Million |
-22.93% |
| 2023-12-31 | CA$12.73 Million ≈ $9.21 Million |
+2.53% |
| 2022-12-31 | CA$12.42 Million ≈ $8.98 Million |
+101.67% |
| 2021-12-31 | CA$6.16 Million ≈ $4.45 Million |
-15.09% |
| 2020-12-31 | CA$7.25 Million ≈ $5.25 Million |
-53.52% |
| 2019-12-31 | CA$15.60 Million ≈ $11.28 Million |
+6.65% |
| 2018-12-31 | CA$14.63 Million ≈ $10.58 Million |
+33.89% |
| 2017-12-31 | CA$10.93 Million ≈ $7.90 Million |
+65.80% |
| 2016-12-31 | CA$6.59 Million ≈ $4.77 Million |
+26.55% |
| 2015-12-31 | CA$5.21 Million ≈ $3.77 Million |
+4968.41% |
| 2014-12-31 | CA$102.73K ≈ $74.31K |
-- |
About Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more